FAST NEWS: Henlius expects first-ever annual profit on strong drug sales
The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Monday it expects to report a net profit of 500 million yuan ($69.5 million) or more for 2023, reversing a loss of 695 million…
Biosimilar Specialist Henlius Takes Off. Now Comes the Hard Part
Fosun Pharma-backed company posts huge revenue jump in the second half of last year, as it boosts production and signs more global licensing deals to stay ahead of competition Key…
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
ECARX reports its first profit, expects added revenue from Volkswagen tie-up
ECX.US
-
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK
-
NaaS drives into third quarter with first-ever quarterly non-IFRS profit
NAAS.US
-
Leapmotor jumps to first-ever quarterly profit
9863.HK
-
NEWS WRAP: VNET records first annual profit in three years
VNET.US
-
Baozun returns to the black as Gap expansion accelerates
9991.HK BZUN.US
